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Abstract The objective of this study was to evaluate the
impact of palivizumab prophylaxis on respiratory syncytial
virus (RSV) hospitalizations among children with hemo-
dynamically signiﬁcant congenital heart disease (CHD).
In2003,theAmericanAcademyofPediatrics(AAP)revised
the bronchiolitis policy statement and recommended the use
of palivizumab in children\24 months old with hemody-
namically signiﬁcant CHD (HS-CHD). California statewide
hospital discharge data from years 2000–2002 (pre-AAP
policy revision) were compared to those from years 2004–
2006 (post-AAP policy revision). Hospitalizations due to
RSV bronchiolitis for children\2 years of age were iden-
tiﬁed by IDC-9 CM codes 4661.1, 480.1, and 079.6 as the
Principal Diagnosis. Children with CHD and children with
HS-CHD were identiﬁed by the codiagnoses. The
overall RSV hospitalization rate was 71 per 10,000 chil-
dren\2 years of age. Of all RSV hospitalizations, 3.0%
were among children with CHD, and 0.50% among children
with HS-CHD. HS-CHD patients accounted for 0.56% of
RSV hospitalizations in 2000–2002, compared to 0.46%
RSV hospitalizations in 2004–2006. That represents a 19%
reduction in RSV hospitalizations among HS-CHD patients
after 2003. The 19% decrease in RSV hospitalizations
equates to seven fewer hospitalizations (76 hospital days)
per year among HS-CHD patients. We conclude that, since
the recommendation of palivizumab for children with
HS-CHD in 2003, the impact on RSV hospitalizations in
California among HS-CHD patients has been limited.
Consideringthehighcostofpalivizumabadministration,the
cost-beneﬁt of RSV prophylaxis with palivizumab warrants
further investigation.
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Respiratory syncytial virus (RSV) bronchiolitis is a major
cause of hospitalizations for infants and children\2 years
of age [13]. RSV immune globulin was the ﬁrst licensed
product for prevention of severe RSV infection [16]. RSV
immune globulin, which is no longer in production, was
not indicated for infants with cyanotic congenital heart
disease (CHD) because of worse outcomes in infants with
cyanotic CHD as shown in a preapproval clinical trial [14].
Palivizumab (Synagis; Med-Immune, Gaithersburg, MD) is
an anti-RSV, humanized murine, monoclonal antibody that
aims to provide passive immunity for the recipient [12].
Palivizumab is administered by monthly injections during
the RSV season to patients at risk for severe RSV infection
[1]. When palivizumab was ﬁrst studied in children with
prematurity, it was shown to reduce RSV-associated hos-
pitalizations by 55% [15].
The results of a multicenter, randomized, double-blind,
placebo-controlled trial of palivizumab in 1287 children
with hemodynamically signiﬁcant CHD (HS-CHD), funded
by MedImmune, Inc., were published in 2003 [6]. This
study showed a 45% reduction in RSV hospitaliza-
tions (p = 0.003) for children given prophylaxis with
palivizumab compared with placebo [6]. Two months fol-
lowing the publication of this study, the American Acad-
emy of Pediatrics (AAP) revised their policy statement to
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DOI 10.1007/s00246-009-9577-0recommend RSV prophylaxis with monthly injections of
palivizumab for children age 24 months or younger who
have HS cyanotic or acyanotic CHD [2].
Several studies have evaluated the cost-effectiveness of
RSV prophylaxis using palivizumab [5, 9, 11]. The esti-
mates of palivizumab effect on RSV-related hospitaliza-
tions used in these cost-effectiveness studies were taken
from the results of clinical trials under controlled research
settings. However, it is unclear whether the results from
clinical trials can be achieved in the ‘‘real world.’’ Decision
makers in health and medical care are increasingly inter-
ested in using reliable scientiﬁc evidence to support clinical
and health policy choices; however, much of the currently
available scientiﬁc evidence may not be applicable in real-
world settings. Practical scientiﬁc evidence is essential in
improving care and promoting efﬁcient use of ﬁnite
resources. There is a growing trend toward emphasizing
meaningful and practical clinical studies that can help
answer real questions faced by decision makers [3].
The objective of this study is to evaluate the actual
impact of palivizumab in reducing RSV-related hospital-
izations among children with HS-CHD using population-
level data from California. Speciﬁcally, the rate of RSV-
related hospitalizations in the 3 years before the release of
the revised AAP statement in 2003 and the rate 3 years
after its release were compared.
Methods
Hospital Discharge Database
This study used the California statewide, abstracted hos-
pital discharge data from the California Ofﬁce of Statewide
Health Planning and Development (OSHPD). The OSHPD
database includes discharges from all nonfederal acute-care
hospitals in California. In this study, the OSHPD data on
hospital discharges from years 2000–2002 and 2004–2006
were used to assess the changes in RSV hospitalizations
3 years prior to and 3 years after the release of the revised
AAP policy statement in 2003. The OSHPD data contain
International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation (ICD-9-CM), discharge diagnosis
and procedure codes assigned by California hospitals to
each individual discharge during the year. Fields are pro-
vided for up to 24 diagnoses and 20 procedures. Although
the clinical information is complete in the public release
version of the data, some demographic information was
masked to protect the privacy of patients.
Of the 6 years included in this study, the ﬁrst 3 years
(2000–2002) were deﬁned as the Prepalivizumab Era,
and the last 3 years (2004–2006) were deﬁned as the
Palivizumab Era. Six California hospitals were among 76
centers which participated in the multicenter clinical trial
of patients with HS-CHD [6]. These hospitals recruited
HS-CHD patients for the palivizumab clinical trial between
1998 and 2002. RSV hospitalizations from these six hos-
pitals were identiﬁed for sensitivity analysis.
Total RSV Hospitalizations
Children\2 years of age with Principal Diagnosis in the
database indicating RSV-related illness were selected for
analysis. RSV-related illnesses included RSV bronchiolitis
(ICD9-CM code 466.11), RSV pneumonia (480.1), and
other RSV (079.6). Severe bronchiolitis cases that required
endotracheal intubation (96.04) or continuous mechanical
ventilation (code 96.72 or 96.71) were identiﬁed using the
ICD-9-CM procedure codes.
Overall, 15.3% of patients’ ages were missing or col-
lapsed (categorized as 1–5 years) in our analytic sample
from OSHPD: we excluded these observations from the
initial analysis but included them in sensitivity analysis.
The percentage of cases with missing or collapsed age was
14.3% in 2000–2002 and 16.0% in 2004–2006.
Vital statistics data of California were used to identify
the population\2 years of age in California for each of the
years 2000–2006. The total numbers of RSV-related hos-
pitalizations for each year between 2000 and 2006 were
calculated. The rate of RSV hospitalization was calculated
as the number of hospitalizations per 10,000 chil-
dren\2 years of age.
Patients with Hemodynamically Signiﬁcant CHD
Among the RSV hospitalizations selected, we identify
patients with CHD by the 24 codiagnosis ﬁelds of each
hospitalization for ICD codes 745–747. The 2003 AAP
policy statement recommends the use of palivizumab for
CHD patients who have HS-CHD, including those who
(1) are receiving medication to control congestive heart
failure, (2) have moderate to severe pulmonary hyperten-
sion, and (3) have cyanotic heart disease. Therefore, we
identiﬁed a subgroup of patients with HS-CHD among the
selected CHD patients with heart failure (ICD9 code 428),
pulmonary hypertension (416.0 and 416.8), or cyanotic
heart diseases. We designated this subgroup the HS-CHD
group, which corresponds to patients with HS-CHD as the
target population for palivizumab use per the revised AAP
policy statement.
Assessing the Impact of Palivizumab on RSV
Hospitalizations
AmongallRSVhospitalizations,thenumberofpatientswith
HS-CHDwasidentiﬁed.BecausetheseverityofRSVseason
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123variesfromyeartoyear,thenumberofRSVhospitalizations
ﬂuctuates from year to year. Therefore, simply comparing
the number of HS-CHD patients hospitalized for RSV in
2000–2002 versus 2004–2006 would be prone to biases.
To estimate the impact of 2003 guidelines on RSV
hospitalizations among HS-CHD patients, HS-CHD
patients were calculated as a percentage of all RSV hospi-
talizations in the Prepalivizumab Era (2000–2002) and in
the Palivizumab Era (2004–2006). This minimized the
effect of year-to-year variations in the severity of RSV. For
our analysis, we made the assumption that if there had been
no revision in AAP bronchiolitis policy in 2003, the pro-
portion of HS-CHD patients among all RSV hospitaliza-
tions would be the same for the Palivizumab Era (2004–
2006) as for the Prepalivizumab Era (2000–2002). Thus, we
calculated the percentage reduction in RSV hospitalizations
among HS-CHD patients as the change in the proportion of
HS-CHD among all RSV hospitalizations between 2000–
2002 and 2004–2006. The formula is as follows:
Nc1=Nt1 ðÞ   Nc2=Nt2 ðÞ ½  = Nc1=Nt1 ðÞ fg   100%
where Nc1 is the number of HS-CHD patients hospitalized
for RSV in 2000–2002; Nc2, the number of HS-CHD
patients hospitalized for RSV in 2004–2006; Nt1, the
number of total RSV hospitalizations in 2000–2002; and
Nt2,thenumberoftotalRSVhospitalizationsin2004–2006.
Estimating the Cost of RSV Hospitalization
The average hospital charge among HS-CHD patients per
RSV hospitalization was calculated. Because hospital char-
gesaregenerallyhigherthantheactualcost,acost-to-charge
ratio of 0.58 (derived from a study on inﬂuenza hospital-
ization at a children’s hospital in 2002) [7] was used to
convert the hospital charges to the costs of hospitalization.
Results
There were a total of 53,207 RSV-related hospitalizations
among children\2 years of age in California from 2000 to
2006. The number of hospitalizations ﬂuctuated over the
years, ranging from 6336 in 2006 to 8712 in 2002. When
calculated as the rate per 10,000 children\2 years of age,
the overall RSV hospitalization rate was 71 per 10,000
children\2 years of age, ranging from 57 per 10,000 in
2006 to 83 per 10,000 in 2002. The RSV hospitalization
rate decreased from 2000 to 2006 (Fig. 1)( R = 0.89,
p\0.01). Overall, 3.0% of all RSV hospitalizations were
patients with CHD, and 0.5% of all RSV hospitalizations
were patients with HS-CHD.
Table 1 summarizes the RSV hospitalizations among all
patients\2 years, patients with CHD, and patients with
HS-CHD. The length of stay was signiﬁcantly longer for
HS-CHDpatients.Notrendofchangeswasnotedinthemean
or median length of stay over time (Fig. 2). Among the RSV
hospitalizations, 2.5% required intubation or use of a venti-
lator. The percentage of HS-CHD hospitalizations requiring
intubation/ventilator was not signiﬁcantly different in 2000–
2002 (17.9%) versus 2004–2006 (18.0%; p = 0.87).
There were 36 deaths among the RSV hospitalizations in
2000–2006. The in-hospital mortality rate was 0.07%, or 1
death per 1478 hospitalizations. The in-hospital mortality
rate decreased from 0.09% in 2000–2002 to 0.06% in
2004–2006. There were ﬁve deaths among HS-CHD
patients in California, of which four occurred prior to 2003
and one after 2003.
Impact of Palivizumab Prophylaxis
We calculated that 0.56% of all RSV hospitalizations in
2000–2002 were HS-CHD patients, whereas 0.46% of all
RSV hospitalizations in 2004–2006 were HS-CHD
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Fig. 1 Annual rate of RSV-related hospitalizations per 1000
infants\2 years of age in California, 2000–2006
Table 1 Characteristics and outcomes of respiratory syncytial virus (RSV) hospitalizations
RSV hospitalizations Total N Length of stay Intubation (%) Mortality
All 53,207 3.6 ± 3.9 (3 days) 2.6 0.07% (n = 36)
Among CHD patients 1,596 (3.0%) 7.1 ± 10.3 (5 days) 9.7 0.63% (n = 10)
Among HS-CHD patients 266 (0.5%) 10.3 ± 18.0 (6 days) 18.0 1.90% (n = 5)
CHD congenital heart disease; HS-CHD hemodynamically signiﬁcant CHD
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123patients. If there had been no policy revision in 2003 to
expand palivizumab use, the proportion of RSV hospital-
izations with HS-CHD in 2004–2006 would have been
0.56% (the same as the proportion in 2000–2002). There-
fore, there would have been a total of 118 hospitalizations
of HS-CHD patients in 2004–2006 (0.56% of 20,881 total
RSV hospitalizations in California in 2004–2006). In
2004–2006, there were 96 observed RSV hospitalizations
of HS-CHD patients. Subtracting 96 from 118, we derive
22 fewer hospitalizations for RSV in the Palivizumab Era
(or an average of 7 fewer hospitalizations per year) as a
result of the AAP policy expansion of palivizumab pro-
phylaxis for HS-CHD patients. The reduction of 22 RSV
hospitalizations for HS-CHD patients in 2004–2006 was
equivalent to a total of 227 hospital days, that is, a decrease
of 76 hospital days per year.
Sensitivity Analysis
In a sensitivity analysis, the 15.3% hospitalizations with
incomplete age information were included in the analysis,
assuming that all of these hospitalizations were among
patients\2 years of age. The overall hospitalization rate
showed a trend of decrease similar to that shown in Fig. 1:
from 9.85 hospitalizations per 1000 in 2002 to 6.95 hos-
pitalizations in 2006. In calculating the number of RSV
hospitalizations among HS-CHD patients, the reduction in
RSV hospitalizations was 21 from the Prepalivizumab Era
(2000–2002) to the Palivizumab Era (2004–2006), or an
average of 7 fewer hospitalizations per year since 2003.
Six hospitals in California participated in the pali-
vizumab clinical trial and recruited HS-CHD patients for
palivizumab use in the Prepalivizumab Era [6]. The RSV
hospitalizations in these hospitals in 2000–2006 accounted
for 9.9% of all RSV hospitalizations. Of HS-CHD patients
hospitalized for RSV, 32.2% were admitted to these six
hospitals in the Prepalivizumab Era, which was not sig-
niﬁcantly different from the 33.3% in the Palivizumab Era
(p = 0.83). When these six hospitals were excluded from
analysis, it was calculated that the total reduction in HS-
CHD hospitalizations was 20 hospitalizations from the
Prepalivizumab Era to the Palivizumab Era.
Cost of RSV Hospitalization
The average hospital charge among HS-CHD patients was
$70,365, and that per RSV hospitalization was $40,812.
Therefore, the total cost saved in the Palivizumab Era was
$897,864, from 22 hospitalizations avoided, or a savings of
$299,288 in California per year.
Discussion
In the pivotal clinical trial that led to FDA approval of
palivizumab use in HS-CHD patients and the AAP policy
revision statement in 2003, a reduction in hospitalization
rate of 45% in the palivizumab group, compared with the
placebo group, was reported [6]. In the current study, using
population-level hospitalization data from California, we
found that the reduction in RSV hospitalization rate for HS-
CHD patients was\20%, or an equivalent of seven fewer
RSV hospitalizations per year for HS-CHD patients.
The overall incidence of RSV hospitalization decreased
during the study period 2000–2006 (Fig. 1). The steep
decline in RSV incidence after 2003, which temporally
correlated with the release of the AAP statement, suggests
an effect of palivizumab prophylaxis on overall RSV
hospitalizations. Another possible explanation for the
decrease in overall RSV hospitalizations during the study
period is a change in clinical practice, that those not-so-
sick patients were not as likely hospitalized in the later era.
We were not able to determine the cause of the decline in
RSV hospitalizations using our data.
We found that the effect of palivizumab prophylaxis on
HS-CHD patients was relatively limited. Why did pali-
vizumab reduce hospitalizations by 45% in the clinical trial
but by only 19% in the actual hospitalization data from
California? A likely explanation for this discrepancy is
patient compliance. The administration of palivizumab
requires monthly intramuscular injections during the RSV
season, typically 5 or 6 months per year. In clinical trials
with a well-deﬁned, supported, and controlled research
environment, the compliance of health-care providers and
patients is ‘‘artiﬁcially’’ elevated. In reality, ensuring
compliance with a monthly injection regimen is difﬁcult.
While the reduction in hospitalizations of 45% in a
clinical trial seemed impressive and was statistically
0
2
4
6
8
10
12
14
2000 2001 2002 2003 2004 2005 2006
Year
A
v
e
r
a
g
e
 
H
o
s
p
i
t
a
l
 
L
e
n
g
t
h
 
o
f
 
S
t
a
y
 
(
D
a
y
s
)
All CHD HS-CHD
Fig. 2 Average length of stay (days) for all patients\2 years of age
(ﬁlled circles), patients with congenital heart disease (CHD; ﬁlled
squares), and patients with cyanotic CHD or heart failure (HS-CHD;
open circles), 2000–2006
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123signiﬁcant, the actual reduction in the number of hospi-
talizations among 1287 study subjects (N = 639 in the
palivizumab group) was 29 hospitalizations over four RSV
seasons, which is a reduction of approximately 7 hospi-
talizations per year. Considering the high cost of pali-
vizumab use, the additional cost of administering the
injections, and the burden on the patients and families, the
impact of palivizumab on RSV hospitalizations of HS-
CHD patients is very limited from a societal point of view.
The question of whether palivizumab use in high-risk
infants is cost-effective has been a topic of discussion
among some investigators. The ﬁrst study on the cost-
effectiveness of palivizumab use among preterm infants
was reported by Joffe et al. in 1999 [8]. Joffe et al. used
data from the Northern California Kaiser Permanente
Medical Care Plan and found that palivizumab prophylaxis
would be cost-effective in only one of eight subgroups
studied (the subgroup of infants born at 23–32 weeks of
gestation, with[28 days’ oxygen requirement, and neo-
natal intensive care unit discharge between September and
November) [8]. In a study of the North Carolina Medicaid
Program, Wegner et al. reported that palivizumab use in
infants 32 to 35 weeks of gestation did not provide a cost
savings [17]. In fact, the cost per person in the palivizumab
prophylaxis group was more than 10 times the per-person
cost in the group that did not receive palivizumab pro-
phylaxis ($5434 vs. $505; p\0.0001) [17].
Using a decision-analysis model and a hypothetical
cohort of 10,000 CHD patients, Yount and Mahle found
that the cost to prevent 1 day of hospitalization is three
times the cost of 1 day in the hospital [18]. Of note, one
may argue that Yount and Mahle have overestimated the
effectiveness of palivizumab in actual practice settings by
using the estimates from the MedImmune trial [6], which
reported a 45% reduction in hospitalizations. Using a his-
torical cohort of 527 infants with CHD born in Norway
from 1987 to 2004, Meberg and Bruu calculated that the
expense of palivizuamab prophylaxis could be as high as
31 times that of hospital treatment [10].
Since the release of the AAP policy statement in 2003
[2], the use of palivizumab for RSV prophylaxis among
children with CHD has increased signiﬁcantly. In the
Palivizumab Outcomes Registry (a voluntary report system
that does not include all CHD patients receiving pali-
vizumab), the number of subjects with CHD enrolled in the
registry increased more than six times from 2000–2001
(N = 102) to 2003–2004 (N = 688) [4]. While data after
2004 are not available from the registry, it is likely that the
increase in CHD patients continued. The insurance com-
panies and patients will bear the immediate burdens of high
palivizumab cost and the unfavorable cost-to-savings ratio.
The ultimate burden is passed on to our health-care system.
We believe that our ﬁndings provide additional population-
level information that can be helpful to health-care pro-
viders, decision makers, and policymakers in considering
the cost and beneﬁt of palivizumab use in children with
HS-CHD. Further studies focusing on cost-effectiveness
and cost-beneﬁt analyses of palivizumab prophylaxis are
needed to guide practice recommendations.
Our study has several limitations. First, we conducted an
observational study of a ‘‘natural experiment’’ rather than a
prospective experimental study. Observational studies are
prone to historical biases and other unmeasured con-
founders. To truly measure the impact of RSV prophylaxis
on children with HS-CHD, the ideal approach would be a
population-level experimental design in the real practice
settings. However, such a study would be enormously
expensive to conduct. Second, our study used an admin-
istrative database on hospital discharge. Hospital discharge
data are prone to incomplete information and miscoding.
The RSV hospitalization rate for children\2 years of age
in this study was comparable to that in other population-
based studies. Although 15% of the data were missing
information on age, a sensitivity analysis was conducted
demonstrating similar results and conclusions. Third, six
hospitals in California participated in the MedImmune
palivizumab trial from 1998 to 2002 [6]. It might be pos-
sible that these six hospitals, which were using pali-
vizumab in HS-CHD patients before 2003, could affect
the comparison between the Prepalivizumab Era (2000–
2002) and the Palivizumab Era (2004–2006). In sensitivity
analysis, we excluded RSV hospitalizations in these six
hospitals from our study sample and found similar results.
Furthermore, there might be off-label use of Synagis in
HS-CHD patients prior to the 2003 recommendation,
however, there are no data to assess the extent of off-label
use before 2003.
Despite these limitations, our study shows that, using
actual California hospitalization data, after the 2003 AAP
bronchiolistis policy revision/expansion, a decrease of only
seven RSV hospitalizations per year was achieved for
children with HS-CHD. The ﬁndings of our study warrant
further investigation of patient compliance and cost-
effectiveness of RSV prophylaxis with palivizumab in
patients with HS-CHD.
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